REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
10.48
+0.24 (2.34%)
At close: Jun 26, 2026, 4:00 PM EDT
10.40
-0.08 (-0.76%)
After-hours: Jun 26, 2026, 7:59 PM EDT
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$236,717
Profits / Employee
-$781,704
Market Cap
541.79M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 246 |
| ProKidney | 231 |
| Kyverna Therapeutics | 129 |
| Assembly Biosciences | 73 |
| Rezolute | 68 |
| Prothena Corporation | 67 |
| Altimmune | 57 |
| Contineum Therapeutics | 51 |
RGNX News
- 3 days ago - Regenxbio completes dosing in confirmatory study of RGX-202 - TheFly
- 3 days ago - REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 - PRNewsWire
- 5 days ago - Regenxbio price target raised to $32 from $27 at Baird - TheFly
- 5 days ago - H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission - TheFly
- 5 days ago - Regenxbio aligns with FDA on path forward for Navsunli - TheFly
- 5 days ago - REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II - PRNewsWire
- 6 days ago - FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports - Reuters
- 6 days ago - Regenxbio up 25% after saying FDA will reverse rejection, consider application - TheFly